Close menu




January 14th, 2020 | 10:54 CET

Ballard Power, dynaCERT, Tesla - the strength of innovations and solutions

  • Innovations
Photo credits: pixabay.com

On the capital market investors find an infinite variety of possibilities to invest their money. There are listed companies that have a history and are valued on the basis of compliance with prospects and fundamentals. And then there are innovative companies that attract capital regardless of all valuation parameters because they have a product that solves problems and arouses desires. If the product is also scalable, then the potential of the shares is often exorbitant, depending on the market size.

time to read: 1 minutes | Author: Mario Hose
ISIN: CA26780A1084 , CA0585861085 , US88160R1014

Table of contents:


    Ballard Power with hydrogen

    The Canadian fuel cell manufacturer Ballard Power has experienced a veritable price rally over the past 12 months. During this period, the company's share price rose from below EUR 2.80 to over EUR 9.50. The shareholders were able to achieve a return of over 230%.

    The market capitalization is now quoted at over 2 billion EUR. The topic of hydrogen in modern mobility is gaining more and more interest and based on that investors are looking for investment opportunities that are active in this field with scalable products.

    dynaCERT makes diesel greener

    Also located in Canada is the innovative company dynaCERT. After more than 15 years of research and development, the experts for hydrogen technologies were able to bring a device to series production readiness with which diesel engines can be retrofitted. The advantage of the technology is that the consumption of diesel can be reduced by up to 18% and, in addition, emissions of NOx, carbon dioxide and particulate matter are also significantly reduced.

    As currently circa one billion diesel engines are in operation and the use of dynaCERT's HydraGEN technology not only offers high savings in fuel consumption but also protects the environment, the share price could increase from below EUR 0.17 to over EUR 0.72 in the past 12 months. With a market value of EUR 230 million, the company is still a lightweight compared to Ballard Power.

    Tesla and the battery car

    Tesla from the USA is a prime example of a new trend. The manufacturer of battery cars has been the focus of reporting for over a decade. The founder at the top of the company is Elon Musk. He is driving Tesla's innovations forward and his announcements are causing euphoria and imagination on the capital market. It's hard to imagine that Tesla today would have a valuation of over EUR 81 billion if Tesla had been led by an employed CEO over the past ten years.

    Musk is there with passion and emotion, and this is the only way to keep the company continuously alive with new cash injections. The share price increased by over 60% from EUR 290.00 to EUR 475.00 in the comparison period. Ten years ago, Tesla shares changed hands at less than EUR 15.00, which clearly shows how enormous the potential of innovations and trends can be.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by André Will-Laudien on September 8th, 2026 | 09:40 CEST

    Biotech: Time to Bet on the Rebound! Evotec and BioNxt in the Takeover Spotlight, Bayer and BioNTech Flush with Cash

    • Biotech
    • Biotechnology
    • Innovations
    • Takeover
    • rebound

    After a long dry spell, the biotech sector is on the cusp of a spectacular turnaround, offering bold investors the potential for significant returns. Many innovative biotech stocks are trading well below their all-time highs, yet almost unnoticed, the next major rally is already taking shape behind the scenes. The huge cash reserves of industry giants Bayer and BioNTech are currently fueling takeover speculation across the sector. This colossal capital, running into the billions, is desperately seeking new growth drivers, suddenly putting smaller players on the radar of potential acquirers. At the very top of the hunters' watchlist are the hard-hit Evotec and the disruptive newcomer BioNxt. Both companies boast top-class technology platforms, which, at current levels, almost seem like an exclusive clearance sale. Investors who keep their eyes open and position themselves strategically for the major rebound could get ahead of the looming wave of consolidation. The conditions for an explosive catch-up rally have rarely been this favorable.

    Read

    Commented by Fabian Lorenz on September 1st, 2026 | 07:45 CEST

    Potential Moderna-Style Share Surge? Takeover Candidates Evotec, Valneva and Vidac Pharma in Focus — Analysts Bullish

    • Biotechnology
    • Pharma
    • Innovations
    • Oncology

    Moderna has shaken up the biotech market with its breakthrough in the fight against skin cancer. Partner Merck has received somewhat less attention in the coverage, despite preparing for the eventual patent expiration of one of its blockbuster drugs. Other pharmaceutical companies will also need to replenish their pipelines in the coming years. As a result, the takeover merry-go-round is likely to pick up speed again, potentially electrifying investors. One hot candidate is Vidac Pharma. Recruitment for its Phase 2B trial into high-risk actinic keratosis, a precancerous skin condition, has been completed. The results could provide a catalyst for the stock. Valneva's share price has recently risen sharply. Could its partner Pfizer eventually make a move? Analysts are recommending the stock. And what about perennial takeover candidate Evotec? Shareholders and potential buyers are currently giving the share a wide berth. Yet there is a "Buy" recommendation on the table.

    Read

    Commented by Tarik Dede on August 17th, 2026 | 07:55 CEST

    Cancer in Focus: Merck & Co., Vidac Pharma and AstraZeneca

    • Biotechnology
    • Biotech
    • Cancer
    • Innovations
    • Pharma
    • patents

    According to the International Agency for Research on Cancer (IARC), part of the WHO, there are currently around 20.6 million new cancer cases worldwide. The annual death toll is estimated at approximately 10 million people. In recent years, more than 53 million people globally have received a cancer diagnosis. According to the WHO, the number of new cases per year is expected to rise to about 35 million by 2050. Two factors are generally cited as the main drivers: demographic change, with the global population getting older, as well as rising rates of obesity, physical inactivity, smoking and air pollution in many countries. Unsurprisingly, the oncology market is correspondingly lucrative. Oncology is the world's largest pharmaceutical market. There is, however, also some good news: the age-adjusted risk of dying from cancer is declining thanks to earlier detection, targeted therapies and advances in immuno-oncology. Today, we take a closer look at this market through the stocks of Merck & Co., Vidac Pharma and AstraZeneca.

    Read